5 completed, 2 active not recruiting, 2 recruiting, 1 terminated. 6 Phase 1, 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Recruiting 1, Unknown 1 |
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Recruiting 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow OSE Immunotherapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor OSE2101, Docetaxel, NGS HLAA2 assay - Patients With Non-Small Cell Lung Cancer | Phase 3 | Recruiting | OSE Immunotherapeutics | 363 | 2024-12-03 | 2026-10-02 |
| Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg - Solid Advanced Tumor, Lymphoma | Phase 1 / Phase 2 | Recruiting | OSE Immunotherapeutics | 41 | 2022-12-20 | 2026-06-04 |
| OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC OSE2101, Pembrolizumab 25 MG/ML [Keytruda] - Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Active not recruiting | ARCAGY/ GINECO GROUP | 180 | 2021-08-05 | 2024-12-02 |
| Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation: FIRsT Study FR104 - Kidney Transplantation | Phase 1 / Phase 2 | Completed | Nantes University Hospital | 10 | 2021-06-28 | 2026-01-15 |
| To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults CoVepiT (OSE13E) - Coronavirus Disease (COVID-19) | Phase 1 | Unknown | OSE Immunotherapeutics | 48 | 2021-05-26 | 2021-06-09 |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC FOLFIRI, OSE2101 - Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer | Phase 2 | Active not recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 106 | 2021-04-10 | 2025-07-25 |
| Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis OSE-127, Placebo - Ulcerative Colitis | Phase 2 | Completed | OSE Immunotherapeutics | 136 | 2020-10-02 | 2026-06-23 |
| A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours BI 765063, BI 754091 - Solid Tumor, Adult | Phase 1 | Completed | OSE Immunotherapeutics | 100 | 2019-04-16 | 2025-06-26 |
| Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects OSE-127, Placebo - Healthy Subjects | Phase 1 | Completed | OSE Immunotherapeutics | 63 | 2018-12-19 | 2019-12-12 |
| OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure OSE2101, Docetaxel, Pemetrexed - Non Small Cell Lung Cancer | Phase 3 | Terminated | OSE Immunotherapeutics | 219 | 2016-02-12 | 2024-02-02 |
| Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104 FR104, Placebo - Rheumatoid Arthritis, Complication of Transplant | Phase 1 | Completed | OSE Immunotherapeutics | 64 | 2015-04-01 | 2016-07-21 |
Carcinoma, Non-Small-Cell Lung (3) · Colitis, Ulcerative (2) · Inflammatory Bowel Diseases (2) · Arthritis, Rheumatoid (1) · COVID-19 (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Recurrence (1)
Docetaxel (2) · Fluorouracil (1) · IDM 2101 (1) · IFL protocol (1) · Irinotecan (1) · Leucovorin (1) · Pemetrexed (1) · pembrolizumab (1)
Belgium (8) · France (7) · Germany (3) · Hungary (3) · Poland (3) · Spain (3) · Italy (2) · United Kingdom (2) · United States (2) · Belarus (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1) · Georgia (1)
Dominique Costantini, Dr (1) · Silvia Comis, MD (1) · Steven Ramael (1)
PMID 37704166, PMID 39155847, PMID 42034003
2015 (2), 2018 (2)